In preclinical model of HPV + oral cancer, intratumoral injection of STING agonist combined with systemic treatment with anti-PD-1 antibodies and anti-CTLA-4 antibodies resulted in sustained tumor regression in 71% of mice, significantly higher than the efficacy of PD-1blocker alone (104). This evidence concerns the gene PDCD1 and neoplasm.